Overview

The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)

Status:
RECRUITING

Trial end date:
2027-12-30

Target enrollment:

Participant gender:

Summary

A multicenter, open-label, randomized study to report the efficacy and safety of teriflunomide plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with newly diagnosed primary immune thrombocytopenia (ITP).

Phase:

PHASE2

Details

Lead Sponsor:

Peking University People's Hospital

Collaborators:

Cisen Pharmaceutical CO., LTD.
Peking University Health Science Center

Treatments:

Dexamethasone
teriflunomide